Magellan Rx MANAGEMENT

TEAM KENTUCKY

Pharmacy Quarterly Newsletter

December 2022 Volume 13, Number 4

THE NUMBERS LISTED BELOW ARE FOR FEE-FOR-SERVICE (FFS) SUPPORT

PHARMACY SUPPORT CENTER

1-800-432-7005

24 hours per day/7 days per week
For claim assistance, early refill overrides, and lock-in overrides

CLINICAL SUPPORT CENTER PRIOR AUTHORIZATIONS

1-800-477-3071

24 hours per day/7 days per week

DIABETIC SUPPLY QUESTIONS

Prior Authorization

1-800-477-3071

PROVIDER SERVICES

1-877-838-5085

M–F, 10:30 a.m.–4:30 p.m. (ET)
Providers should contact Provider Services for inquiries regarding enrollment and changes.

MEMBER SERVICES

1-800-635-2570

M–F, 8:00 a.m.–5:00 p.m. (ET)
Recipients should contact Member Services for medication replacement requests and co-pay and benefit information.

WEBSITES

Kentucky Department for Medicaid Services
DMS Pharmacy Website
Magellan Medicaid Administration
https://kentucky.magellanmedicaid.com

PROVIDER EDUCATION and FFS HELP

For onsite education presentations or any other questions, concerns, or feedback regarding Fee-for-Service Medicaid, please contact Magellan Rx Management at kyproviders@magellanhealth.com. Provider education is free of charge.

Vaccine Counseling

In accordance with the National Council for Prescription Drug Programs (NCPDP) guidance, the Department for Medicaid Services (DMS) has released billing guidance for Vaccine Counseling for Medicaid members. Please follow the link below to the notice for more information.

https://kyportal.medimpact.com/sites/default/files/2022-10/kym_vaccine_counsel_1022.pdf

MAT Drug Dispense Fee FAQ and Provider Notice

On November 1st and October 1st of this year, the new dispensing fee changes for Medication-Assisted Treatment (MAT) drugs (oral buprenorphine products) went into effect for Fee-for-Service and KY Managed Medicaid members, respectively. The Frequently Asked Questions (FAQ) document was created in response to provider community inquiries. Below you will find links for this document, as well as the provider notice regarding the changes.

https://kyportal.medimpact.com/sites/default/files/2022-10/kym__mat_faqs__10_22.pdf

https://kyportal.magellanmedicaid.com/public/client/static/kentucky/documents/KY-ProviderNotice-282-20221005.pdf

Quinapril/HCTZ Recall

Aurobindo has initiated a voluntary recall of 2 lots of quinapril/HCTZ tablets USP 20 mg/12.5 mg. This product is in the ACEI + Diuretic Combinations class on the Preferred Drug List (PDL). This recall is to the consumer level due to presence of the nitrosamine drug substance related impurity (NDSRI), N-nitroso-quinapril, above the proposed interim limit. There will be no changes to the PDL due to this recall. Aurobindo began shipping the subject batches nationwide in May 2021. The included products have an expiration date of January 2023.[1]

1. Aurobindo Pharma USA, Inc. Initiates Voluntary Nationwide Recall of Two (2) Lots of Quinapril and Hydrochlorothiazide Tablets USP 20mg/12.5mg, Due to the Detection of N-Nitroso Quinapril Impurity. Accessed December 1, 2022. https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/aurobindo-pharma-usa-inc-initiates-voluntary-nationwide-recall-two-2-lots-quinapril-and

FDA Warnings Reminder: SLGT-2 inhibitors and DPP-4

In 2018, the U.S. Food and Drug Administration (FDA) warned that there were notable cases of a rare but serious infection of the genitals and area around the genitals (necrotizing fasciitis of the perineum) associated with sodium-glucose cotransporter-2 (SGLT2) inhibitors. [2]

Prior, in 2016 the FDA warned that type 2 diabetes medications containing saxagliptin and alogliptin may increase the risk of heart failure, particularly in those who already have heart or kidney disease. These medications are in the dipeptidyl pedptidase-4 (DPP-4) inhibitor class of drugs. Both arenon-preferred on the PDL.[3]

For more information regarding these warnings, please follow the links to the sources below.

2. FDA warns about rare occurrences of a serious infection of the genital area with SGLT2 inhibitors for diabetes. Accessed December 1, 2022.https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-rare-occurrences-serious-infection-genital-area-sglt2-inhibitors-diabetes
3. FDA Drug Safety Communication: FDA adds warnings about heart failure risk to labels of type 2 diabetes medicines containing saxagliptin and alogliptin. Accessed December 1, 2022. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-adds-warnings-about-heart-failure-risk-labels-type-2-diabetes

Influenza and COVID-19 Co-administration

Studies evaluating both the co-administration and separate administration of COVID-19 and influenza vaccines found comparable results with the activated immune response. There was a similar or slightly higher chance of side effects noted after co-administration with no specific safety concerns.[4]

Giving both vaccinations at the same time may be more convenient for patients. Alternatively, there is not a recommended time to wait between getting the flu or COVID-19 vaccine if not administered concurrently.

These vaccines can be administered in either the same arm (at least one inch apart) or in different arms.

Consider administering the COVID-19 vaccine and high-dose or adjuvanted flu vaccine into different arms to help reduce local side effects.[5]

4. Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States. Accessed on December 5th, 2022. https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html#recommendations
5. Getting a Flu Vaccine and a COVID-19 Vaccine at the Same Time. Accessed on December 5th, 2022. https://www.cdc.gov/flu/prevent/coadministration.htm

Questions/additional information

Please direct any questions to kyproviders@magellanhealth.com for Fee-For-Service members and to KYMCOPBM@medimpact.com for Managed Care Organization (MCO) members.